MY184076A - Hpv chimaeric particle - Google Patents
Hpv chimaeric particleInfo
- Publication number
- MY184076A MY184076A MYPI2014700894A MYPI2014700894A MY184076A MY 184076 A MY184076 A MY 184076A MY PI2014700894 A MYPI2014700894 A MY PI2014700894A MY PI2014700894 A MYPI2014700894 A MY PI2014700894A MY 184076 A MY184076 A MY 184076A
- Authority
- MY
- Malaysia
- Prior art keywords
- hpv
- chimaeric
- particle
- vlp
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA201108841 | 2011-12-01 | ||
| PCT/IB2012/056912 WO2013080187A1 (en) | 2011-12-01 | 2012-12-03 | Hpv chimaeric particle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY184076A true MY184076A (en) | 2021-03-17 |
Family
ID=48534756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014700894A MY184076A (en) | 2011-12-01 | 2012-12-03 | Hpv chimaeric particle |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9771397B2 (enEXAMPLES) |
| EP (1) | EP2785842A4 (enEXAMPLES) |
| JP (1) | JP6228922B2 (enEXAMPLES) |
| KR (1) | KR102013801B1 (enEXAMPLES) |
| CN (1) | CN103890177B (enEXAMPLES) |
| AU (1) | AU2012345443B2 (enEXAMPLES) |
| BR (1) | BR112014012491A2 (enEXAMPLES) |
| CA (1) | CA2850293C (enEXAMPLES) |
| HK (1) | HK1198703A1 (enEXAMPLES) |
| IL (1) | IL232584B (enEXAMPLES) |
| IN (1) | IN2014DN03054A (enEXAMPLES) |
| MX (1) | MX355352B (enEXAMPLES) |
| MY (1) | MY184076A (enEXAMPLES) |
| PH (1) | PH12014500466A1 (enEXAMPLES) |
| RU (1) | RU2642287C2 (enEXAMPLES) |
| SG (1) | SG11201401579UA (enEXAMPLES) |
| WO (1) | WO2013080187A1 (enEXAMPLES) |
| ZA (1) | ZA201403557B (enEXAMPLES) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2845212T3 (es) | 2009-04-13 | 2021-07-26 | Inst Nat Sante Rech Med | Partículas de HPV y usos de las mismas |
| WO2013119877A1 (en) | 2012-02-07 | 2013-08-15 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
| EP3046583B1 (en) * | 2013-09-18 | 2019-02-13 | Aura Biosciences, Inc. | Virus-like particle conjugates for treatment of tumors |
| CN104531741B (zh) * | 2014-08-22 | 2016-08-24 | 天津康希诺生物技术有限公司 | 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用 |
| CN105801704B (zh) * | 2014-12-31 | 2020-06-02 | 艾托金生物医药（苏州）有限公司 | 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用 |
| CN108136039A (zh) | 2015-08-18 | 2018-06-08 | 阿斯皮利安治疗学股份有限公司 | 用于光免疫疗法的组合物、联用及相关方法 |
| CN114699525A (zh) | 2015-08-18 | 2022-07-05 | 乐天医药生技股份有限公司 | 酞菁染料偶联物的制造方法及稳定偶联物 |
| CN108473950A (zh) | 2015-10-30 | 2018-08-31 | 美国政府卫生与公众服务部 | 靶向癌症治疗 |
| BR112019020853A2 (pt) * | 2017-04-04 | 2020-05-12 | Avidea Technologies, Inc. | Vacinas à base de peptídeo, métodos de fabricação e usos das mesmas para induzir uma resposta imune |
| CA3068012A1 (en) | 2017-06-23 | 2018-12-27 | Pathovax Llc | Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses |
| AU2019414934A1 (en) | 2018-12-27 | 2021-06-24 | Verimmune Llc | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors |
| WO2021161179A1 (en) * | 2020-02-10 | 2021-08-19 | University Of Cape Town | Plant produced bovine papillomavirus virus-like particles and pseudovirions |
| AU2021364548A1 (en) | 2020-10-19 | 2023-06-08 | Verimmune Inc. | Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer |
| KR102821363B1 (ko) | 2023-02-06 | 2025-06-13 | 영산대학교산학협력단 | 드론에 장착된 라이다 센서를 기초로 하는 수심 측량 시스템 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU693203B2 (en) * | 1994-05-16 | 1998-06-25 | Merck Sharp & Dohme Corp. | Papillomavirus vaccines |
| IL141130A0 (en) | 1998-08-14 | 2002-02-10 | Merck & Co Inc | Process for purifying human papilloma virus-like particles |
| US20020016372A1 (en) * | 2000-07-31 | 2002-02-07 | Allison Anthony Clifford | Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury |
| US20040063188A1 (en) | 2002-02-14 | 2004-04-01 | Novavax, Inc. | Kit for treating gastrointestinal tract |
| EP1506222B2 (en) * | 2002-05-17 | 2012-05-23 | University of Cape Town | Chimeric human papillomavirus 16 l1 proteins comprising an l2 peptide, virus-like particles prepared therefrom and a method for preparing the particles |
| PL1883701T3 (pl) | 2005-04-29 | 2012-06-29 | Univ Cape Town | Ekspresja białek wirusa w roślinach |
| CN102458440A (zh) * | 2009-04-10 | 2012-05-16 | 约翰·霍普金斯大学 | 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp) |
| CN102215861B (zh) | 2009-06-19 | 2014-10-08 | 艾金株式会社 | 宫颈癌疫苗 |
| MA33440B1 (fr) * | 2009-06-25 | 2012-07-03 | Glaxosmithkline Biolog Sa | Nouvelles compositions |
| WO2011077371A1 (en) * | 2009-12-22 | 2011-06-30 | University Of Cape Town | Method for enhancing the expression of hpv l1 |
-
2012
- 2012-12-03 CN CN201280052968.8A patent/CN103890177B/zh not_active Expired - Fee Related
- 2012-12-03 KR KR1020147010686A patent/KR102013801B1/ko not_active Expired - Fee Related
- 2012-12-03 HK HK14112143.5A patent/HK1198703A1/xx unknown
- 2012-12-03 MX MX2014006520A patent/MX355352B/es active IP Right Grant
- 2012-12-03 CA CA2850293A patent/CA2850293C/en not_active Expired - Fee Related
- 2012-12-03 JP JP2014544038A patent/JP6228922B2/ja not_active Expired - Fee Related
- 2012-12-03 SG SG11201401579UA patent/SG11201401579UA/en unknown
- 2012-12-03 IN IN3054DEN2014 patent/IN2014DN03054A/en unknown
- 2012-12-03 WO PCT/IB2012/056912 patent/WO2013080187A1/en active Application Filing
- 2012-12-03 RU RU2014126587A patent/RU2642287C2/ru not_active IP Right Cessation
- 2012-12-03 AU AU2012345443A patent/AU2012345443B2/en not_active Ceased
- 2012-12-03 US US14/360,524 patent/US9771397B2/en not_active Expired - Fee Related
- 2012-12-03 MY MYPI2014700894A patent/MY184076A/en unknown
- 2012-12-03 PH PH1/2014/500466A patent/PH12014500466A1/en unknown
- 2012-12-03 EP EP12853360.1A patent/EP2785842A4/en not_active Withdrawn
- 2012-12-03 BR BR112014012491A patent/BR112014012491A2/pt not_active IP Right Cessation
-
2014
- 2014-05-13 IL IL232584A patent/IL232584B/en active IP Right Grant
- 2014-05-16 ZA ZA2014/03557A patent/ZA201403557B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2642287C2 (ru) | 2018-01-24 |
| EP2785842A1 (en) | 2014-10-08 |
| HK1198703A1 (en) | 2015-05-29 |
| CA2850293C (en) | 2019-10-08 |
| AU2012345443B2 (en) | 2017-10-26 |
| KR102013801B1 (ko) | 2019-08-23 |
| MX2014006520A (es) | 2014-11-21 |
| RU2014126587A (ru) | 2016-01-27 |
| BR112014012491A2 (pt) | 2017-06-06 |
| EP2785842A4 (en) | 2015-11-25 |
| JP6228922B2 (ja) | 2017-11-08 |
| US9771397B2 (en) | 2017-09-26 |
| KR20140098061A (ko) | 2014-08-07 |
| NZ622595A (en) | 2016-04-29 |
| PH12014500466A1 (en) | 2022-05-11 |
| AU2012345443A1 (en) | 2014-04-17 |
| WO2013080187A1 (en) | 2013-06-06 |
| IL232584A0 (en) | 2014-06-30 |
| IN2014DN03054A (enEXAMPLES) | 2015-05-15 |
| CN103890177A (zh) | 2014-06-25 |
| CA2850293A1 (en) | 2013-06-06 |
| SG11201401579UA (en) | 2014-07-30 |
| ZA201403557B (en) | 2020-10-28 |
| IL232584B (en) | 2018-10-31 |
| JP2015500229A (ja) | 2015-01-05 |
| MX355352B (es) | 2018-04-17 |
| CN103890177B (zh) | 2016-03-09 |
| US20140377367A1 (en) | 2014-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN03054A (enEXAMPLES) | ||
| MX2023014569A (es) | Anticuerpos anti-sirpa. | |
| PH12019502269A1 (en) | Quinazoline derivatives for the treatment of viral infections and further diseases | |
| MX2022007522A (es) | Anticuerpos anti-cd27. | |
| HK1246183A1 (zh) | Hpv疫苗 | |
| PH12017500296A1 (en) | Anti-tigit antibodies | |
| MA40458A (fr) | Méthodes de traitement du cancer du col de l'utérus | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| MX361218B (es) | Análogos de spliceostatina. | |
| EA032929B1 (ru) | Нейтрализующее вирус иммунодефицита человека антитело и способы его применения | |
| PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| PH12014500724A1 (en) | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication | |
| MX343505B (es) | Metodos y composiciones para inhibir la transmision del vih. | |
| WO2015054678A3 (en) | Human papilloma virus therapeutic vaccine | |
| EP2978449A4 (en) | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection | |
| EP3010507A4 (en) | Compositions and methods for potentiating immune response for the treatment of infectious diseases and cancer | |
| EP2601967A4 (en) | MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS | |
| IN2011CH03893A (enEXAMPLES) | ||
| PH12017500928B1 (en) | A rabies composition comprising pika adjuvant | |
| WO2013093629A3 (en) | Modular vaccines, methods and compositions related thereto | |
| IN2014DN10683A (enEXAMPLES) | ||
| WO2011054996A3 (es) | Vacunas para el tratamiento de neoplasias a partir de capsides virales de birnavirus conteniendo antigenos del virus del papiloma humano | |
| UA90646C2 (ru) | Способ лечения часто рецидивирующей хронической герпетической инфекции, вызванной вирусом герпеса простого и и ии типов | |
| UA74055U (ru) | Способ хирургического лечения рефрактерных форм глаукомы | |
| UA59657U (ru) | Способ лечения женщин с фоновыми заболеваниями шейки матки на фоне генитальной герпесвирусной инфекции |